A new type of pegylated interferon, call peginterferon Lambda, caused a faster decline in HBV DNA and hepatitis B surface antigen than the standard pegylated interferon alfa-2a (Pegasys), according to results of a ground-breaking Phase 2 clinical trial presented at the 23rd Conference of the Asian Pacific Association for the Study of the Liver in early June.
The weekly Lambda injections in 80 hepatitis B patients proved
equally effective as standard pegylated interferon alfa-2a (Pegasys)
medication in spurring loss of the hepatitis B “e” antigen. There were
no safety concerns or additional side effects resulting from Lambda
—Christine. M. Kukka, Project Manager, HBV Advocate